Immunodiagnostic Systems

In 1977, a company named RIA UK Limited was established, laying the groundwork for what would become Immunodiagnostic Systems (IDS). This UK-based venture focused on a specialized niche within the medical field: in-vitro diagnostics. Specifically, the company dedicated itself to developing and manufacturing immunoassay kits and automated analyzer technologies for clinical laboratories. The company built its reputation in key clinical areas, particularly endocrinology, with a strong focus on assays for bone and calcium metabolism. A significant moment came in 2004 when the company, then known as Immunodiagnostic Systems Holdings, went public through an IPO. This event provided the capital to expand its reach and product lines. Following the IPO, IDS embarked on international expansion, establishing a presence in the United States in 2003 and later entering markets in China and Brazil. The playbook was clear: develop highly specialized diagnostic tests and create automated systems to improve laboratory efficiency. This strategy culminated in a major turning point. In May 2021, the US-based scientific and healthcare giant PerkinElmer announced its intention to acquire IDS for approximately $155 million. The acquisition was completed in July 2021, integrating IDS into PerkinElmer's EUROIMMUN division to complement its existing portfolio in autoimmune and infectious disease testing. This marked the end of IDS's journey as an independent public company and the start of a new chapter as part of a global diagnostics powerhouse.